Skip to main content

Table 1 Clinical and demographic characteristics of included patients

From: Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study

Characteristica All patients Patients with 4.5 g PIP/TAZ three times daily Patients with 4.5 g PIP/TAZ two times daily
(n = 60) (n = 45) (n = 15)
Female/male (n/n) 17/43 13/32 4/11
Age (years) 63 (54–75) 63 (55–74) 64 (54–78)
BMI (kg/m2) 27 (24–29) 26 (23–29) 29 (26–31)
Severity scores    
 APACHE II score 24 (18–31) 24 (17–32) 24 (18–29)
 SOFA score 11 (9–14) 11 (9–13) 12 (11–17)
Laboratory values    
 CrCl (mL/min) 60 (24–119) 70 (40–130) 11 (6–19)
Organ transplantation (n)    
 Lung 7 6 1
 Liver 8 4 4
Special treatments (n)    
 RRT patients 10 7 3
 ECLA 3 3 0
Site of infection (n)    
 Pneumonia 36 27 9
 Peritonitis 7 4 3
 Catheter associated 5 4 1
 Others 12 10 2
Presence of ARDS (n) 12 11 1
  1. PIP/TAZ piperacillin-tazobactam, BMI body mass index, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, CrCl creatinine clearance of patients without renal replacement therapy, RRT renal replacement therapy, ECLA extracorporeal lung assist, ARDS acute respiratory distress syndrome
  2. aData from day 1 are presented as median (interquartile range) unless otherwise specified